Diabetes/Metabolism/Obesity
Overview
Putting the patient at the center of focus, explore in this webinar recording and CME activity how to treat and manage obesity in a person-centred way. Join our three expert speakers and a person living with obesity, who shares her personal experience, as they provide valuable insights and answer healthcare professionals' questions on obesity management.
Join endocrinologist Nitin Kapoor (India) and nephrologist Holly Kramer (USA) in an educational session that delves into the epidemiology of obesity in the context of CKD, and the mechanisms leading to new-onset renal disease and the progression of pre-existing CKD. The experts also discuss the current evidence supporting the treatment of obesity in CKD patients.
Join them as they explore new pathways and treatment options, emphasizing the importance of a multidisciplinary approach in the ...
This case-based session was organized by the International Society of Endocrinology (ISE) and the International Society of Nephrology (ISN) as part of a mutual commitment to advance the management of overlapping endocrinology and kidney diseases worldwide.
Join nephrologists Steve Chadban (Australia) and Natasha Rogers (Australia) and endocrinologist Pankaj Shah (USA) in a case-based educational session that discusses endocrine and metabolic complications after a kidney transplant.
...
In this session, the speakers give a macro view on obesity by addressing important aspects of the science behind the disease, identifying strategies for the prevention of obesity from a public health perspective, and addressing key aspects of weight reduction, the
prevention of weight regain and
the prevention of weight gain.
In patients with CKD, the decline in GFR reduces the clearance of insulin and many diabetes medications and raises the risk of hypoglycemia with insulin, sulfonylureas and glinides. GLP1 agonists have cardiovascular benefits, and SGLT2 inhibitors significantly decrease kidney and cardiovascular outcomes making them the class of choice for those with CKD. Targets for glycemic control should be individualized taking CKD into consideration, and glycemic control should be monitored with HbA1c, supp...
The experts discuss efficacy of SGLT2
inhibitors in patients with CKDm, safety of SGLIT2 inhibtiors in patients with
CKD, comparative effects of SGLT2i in those with/without type 2 diabetes, efficacy
of new agents tested in recent trials for patients with CKD, and safety
of new agents tested in recent trials for patients with CKD.
Increased morbidity and mortality from COVID-19 in patients with Diabetes Mellitus have been noted in those countries hardest hit by the pandemic. This webinar addresses this association and the optimal management of infected patients with Diabetes Mellitus, with an insight into the impact of COVID-19 on the kidney, association of kidney disease with outcomes and management of COVID-19 disease and considerations for the outpatient management of kidney disease patients in the setting of the COVID...
This course analyses the environmental factors driving obesity, identifies cues during development, plasticity, and determination of the adult phenotype, addresses the role of Endocrine Disruptive Chemicals and the central nervous system in obesity, and gives an insight into the different genetic causes of obesity.Developed in collaboration with Dr Ankia Coetzee (South Africa).
This course explores the advantages and limitations of different anthropometric indicators, analyses the importance of assessing body composition in clinical practice and the concept of Normal Weight Obesity, and gives an insight into emerging concepts in obesity assessment.Developed in collaboration with Dr Nitin Kapoor (India).